NCT02553330

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	Placebo Cream
DRUG	Ruxolitinib Phosphate Cream

Timeline

• Start date: 2015-11-18
• Primary completion: 2017-10-03
• Completion: 2017-10-03
• First posted: 2015-09-17
• Last updated: 2020-12-16
• Results posted: 2020-12-16

Locations

18 sites across 1 country: United States